Moderna News - October 22, 2026
Moderna Shares Plunge After Leak Shows 42% Cancer Risk Cut
Moderna shares fell more than 20% on Thursday after detailed results for its personalized melanoma vaccine, intismeran, developed with Merck, were apparently...
Moderna Drops 12% After a 700% Rally — Can a Single Data Readout Justify a $98 Billion Valuation?
Shares of Moderna plunged 11.9% to $216.65 on Thursday as investors locked in profits from a breathtaking cancer-vaccine rally, with the critical question now...
🔴 Moderna is trading 12% down today as investors reassess valuation before full trial data
Moderna is trading at $216.65 (-11.86%) as investors reassess its valuation after a sharp rally tied to positive Phase 3 melanoma-vaccine news. - Full data...
🔴 Moderna is trading 6% down today ahead of October 24 melanoma-vaccine data
Moderna is trading at $231.05, down 5.95%, as investors position ahead of full Phase 3 melanoma-vaccine data for intismeran with Merck, scheduled for October...
🔴 Moderna is trading 4.3% down amid a broad risk-off session
Moderna is trading at $237.92, with a -4.31% change, amid a broad risk-off session. - The Nasdaq Composite is down 1.57% and the S&P 500 is down 0.95%,...